
💥 MIBC is no longer surgery-first—oncology is rewriting the rulebook. 🩺 Surgery & Chemo (traditional backbone) Radical cystectomy ± peri-op cisplatin chemo remains standard, but morbidity & patient fitness limit its universal application. 🧬 Immunotherapy integration Neo/adjuvant ICB now proven: • CheckMate-274 → Nivolumab improved DFS & OS • AMBASSADOR → Pembrolizumab improved DFS • NIAGARA → Durvalumab peri-op improved DFS & OS 🧪 ctDNA as MRD tool • Detectable ctDNA predicts relapse post-cystectomy • IMvigor010, TOMBOLA, MODERN exploring ctDNA-guided escalation/de-escalation 🚦 → Personalised systemic therapy decisions on horizon. 🎯 ADCs + ICB combos • EV+pembro (EV-302) revolutionised metastatic setting • Now moving peri-op in VOLGA, KEYNOTE-905, KEYNOTE-B15 → Potential to boost cure rates in cisplatin-eligible & ineligible pts. 🛡️ Bladder-sparing strategies • TURBT + systemic therapy → durable CR in select pts (HCRN GU16-257, RETAIN) • Emerging risk-adapted, biomarker-driven pathways • Goal: preserve organ without compromising cure. ➡️ The next decade = convergence of powerful therapeutics + precise biomarkers + risk-adapted strategies. Not just longer survival-cure + quality of life together. 📖 JCO 2025 Review: ascopubs.org/doi/full/10.120… @ASCO @oncoalert @uro_today @theNCI #BladderCancer #Oncology #UroOnc #Immunotherapy #CancerResearch





































